Sara Newman
Nurse Practitioner · Sioux Falls, SDNPI 1679260715
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,828 of the $4,273 with a category attached, or 66.2%. 33 manufacturers reported payments, led by Livanova USA, Inc. at 44.8% of the total. Reporting peaked in 2024 at $2,817 and has fallen 75.9% since, to $679 in 2025. Among nurse practitioner clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $56.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Neurocrine Biosciences, Inc.$402
- AstraZeneca$205
- Biogen$199
- Genentech, Inc.$163
- EMD Serono, Inc.$143
- plus $1K from 27 others
What the payments were for
- Travel & lodging$1,44534%
- Food & beverage$2,82866%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 7 | $1,913 |
| Neurocrine Biosciences, Inc. | 5 | $402 |
| AstraZeneca | 4 | $205 |
| Biogen | 4 | $199 |
| Genentech, Inc. | 2 | $163 |
| EMD Serono, Inc. | 2 | $143 |
| AbbVie | 5 | $123 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| SK Life Science, Inc. | 3 | $116 |
| Acadia Pharmaceuticals Inc | 2 | $94 |
| Pfizer | 5 | $76 |
| Catalyst Pharmaceuticals, Inc. | 3 | $75 |
| Genentech USA, Inc. | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Argenx US, Inc. | 3 | $54 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Eisai Inc. | 2 | $49 |
| CSL Behring | 2 | $36 |
| TG Therapeutics, Inc. | 2 | $34 |
| Merz Pharmaceuticals, LLC | 2 | $33 |
| Boston Scientific | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Neurelis, Inc. | 1 | $25 |
| Microtransponder, Inc. | 1 | $21 |
| Averitas Pharma Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Amylyx Pharmaceuticals, Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Bio Products Laboratory USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,913
- INGREZZA$364
- Mavenclad$124
- ZEPOSIA$121
How this compares
$4,273 in reported general payments places this provider in the 95th percentile of 504 nurse practitioner providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BetaseronInterferon Beta-1b | 16 | $148,791 |
| Nurtec OdtRimegepant Sulfate | 71 | $102,251 |
| CopaxoneGlatiramer Acetate | 15 | $86,075 |
| BriviactBrivaracetam | 47 | $55,624 |
| Emgality PenGalcanezumab-Gnlm | 63 | $42,003 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $11,267 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $11,149 |
| Levetiracetam | 373 | $11,050 |
| Lacosamide | 91 | $10,139 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 363 | $8,047 |
| Pregabalin | 233 | $4,527 |
| Divalproex Sodium ErDivalproex Sodium | 34 | $4,225 |
| Dimethyl Fumarate | 15 | $4,151 |
| Carbamazepine ErCarbamazepine | 66 | $4,074 |
| FingolimodFingolimod Hcl | 20 | $3,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $76 | $102,25171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 nurse practitioner providers in South Dakota.
Other nurse practitioner in Sioux Falls
- Jamie BuschSioux Falls$60K
- Jessica SlabaSioux Falls$41K
- Christopher NelsonSioux Falls$35K
- Katherine EricsonSioux Falls$13K
- Gabrielle PriceSioux Falls$5K
- Jacqueline KelleySioux Falls$5K
- Jessica YoshinoSioux Falls$5K
- Catherine McCulleySioux Falls$5K
- Heather MitzelSioux Falls$5K
- Tiffanie VaneimerenSioux Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.